Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Teladoc

Meridian Bioscience

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases.

Why Teladoc Health, Arcturus And Meridian Are Moving Today

FedEx

Lockheed Martin

Roku

Albertsons Companies

Big Lots

CME Group

3D Systems

Domino's Pizza

Editas Medicine

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Domino's, FedEx, Lockheed, Roku and More of Tuesday Afternoon's Analyst Calls

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.

Did You Miss Out on the Chance for Big Gains from Arcturus Stock?

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study

This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.

Why Is Everyone Talking About Arcturus Therapeutics Stock?

Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical trial for its COVID-19 vaccine candidate. Arcturus last week announced disappointing data from the Phase 1/2 trial conducted in Singapore that sent the stock tumbling 55%.

Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis

Co-Diagnostics

Fulgent Genetics

Inovio Pharmaceuticals

Moderna

Investors in fast-moving biotechs made out like bandits.

These Were the 5 Top Genetics Stocks of 2020

Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.

Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

Blink Charging

Two top performers fell back to earth on Tuesday.

Markets Ease Lower as Arcturus, Blink Charging Plunge

Investors obviously considered these to be underwhelming, however.

Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies.  Barclays called the interim data of the vaccine candidate "disappointing," according to a report cited by Seeking Alpha. Analyst Gena Wang wrote that higher dose animal studies showed some efficacy, but "safety concerns limited further dose escalation." The firm downgraded its rating for Arcturus from "overweight" to "equal weight."  Barclays holds a price target of $46 for the stock. Raymond James also downgraded its rating from "outperform"to "market perform," while Baird analysts downgraded the stock from "outperform" to "neutral" and lowered its price target from $79 to $69. 

Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates (ARCT)

The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.

Why Arcturus Therapeutics Stock Is Plunging Today

An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.

Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-based Arcturus announced interim data for a Phase 1/2 study of its vaccine candidate ARCT-021 that shows a favorable safety profile and a less favorable immunogenicity data.

Why Shares Of Coronavirus Vaccine Developer Arcturus Are Sinking

Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.

Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming'

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Preclinical Data

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

Johnson & Johnson

One's a healthcare giant. The other is a small clinical-stage biotech.

2 Come-From-Behind Stocks That Could Still Win the COVID Vaccine Race

Why Arcturus Therapeutics Stock Is Sinking Today

Novavax

3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now

CureVac B.V

Vaxart

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

4 Small COVID-19 Vaccine Makers to Look Out for in 2021

They each have a key competitive edge that could set them apart.

News for Arcturus Therapeutics Stock (ARCT)